TEVA PHARMACEUTICAL-SP ADR (TEVA) Stock Fundamental Analysis
USA - NYSE:TEVA - US8816242098 - ADR
24.6 USD
+4.14 (+20.23%)
24.5001 USD
-0.1 (-0.41%)
TEVA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. TEVA has a medium profitability rating, but doesn't score so well on its financial health evaluation. TEVA is valued quite cheap, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year TEVA was profitable.
TEVA had a positive operating cash flow in the past year.
In the past 5 years TEVA reported 4 times negative net income.
In the past 5 years TEVA always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of TEVA (-0.39%) is better than 79.17% of its industry peers.
Looking at the Return On Equity, with a value of -2.31%, TEVA is in the better half of the industry, outperforming 79.17% of the companies in the same industry.
TEVA's Return On Invested Capital of 10.49% is amongst the best of the industry. TEVA outperforms 88.54% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for TEVA is significantly below the industry average of 15.46%.
The last Return On Invested Capital (10.49%) for TEVA is above the 3 year average (9.12%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.39% | ||
| ROE | -2.31% | ||
| ROIC | 10.49% |
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
1.3 Margins
TEVA has a Operating Margin of 22.59%. This is amongst the best in the industry. TEVA outperforms 89.58% of its industry peers.
In the last couple of years the Operating Margin of TEVA has grown nicely.
TEVA has a better Gross Margin (50.88%) than 64.58% of its industry peers.
In the last couple of years the Gross Margin of TEVA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.59% | ||
| PM (TTM) | N/A | ||
| GM | 50.88% |
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
2. Health
2.1 Basic Checks
TEVA has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, TEVA has more shares outstanding
TEVA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TEVA has been reduced compared to a year ago.
2.2 Solvency
TEVA has an Altman-Z score of 0.66. This is a bad value and indicates that TEVA is not financially healthy and even has some risk of bankruptcy.
TEVA has a Altman-Z score (0.66) which is in line with its industry peers.
The Debt to FCF ratio of TEVA is 19.36, which is on the high side as it means it would take TEVA, 19.36 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 19.36, TEVA is doing good in the industry, outperforming 75.52% of the companies in the same industry.
TEVA has a Debt/Equity ratio of 2.46. This is a high value indicating a heavy dependency on external financing.
TEVA has a Debt to Equity ratio of 2.46. This is in the lower half of the industry: TEVA underperforms 78.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.46 | ||
| Debt/FCF | 19.36 | ||
| Altman-Z | 0.66 |
ROIC/WACC1.37
WACC7.63%
2.3 Liquidity
A Current Ratio of 1.06 indicates that TEVA should not have too much problems paying its short term obligations.
With a Current ratio value of 1.06, TEVA is not doing good in the industry: 80.73% of the companies in the same industry are doing better.
A Quick Ratio of 0.77 indicates that TEVA may have some problems paying its short term obligations.
TEVA has a Quick ratio of 0.77. This is amonst the worse of the industry: TEVA underperforms 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.77 |
3. Growth
3.1 Past
TEVA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.09%.
TEVA shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.18% yearly.
Looking at the last year, TEVA shows a small growth in Revenue. The Revenue has grown by 2.07% in the last year.
Measured over the past years, TEVA shows a decrease in Revenue. The Revenue has been decreasing by -0.41% on average per year.
EPS 1Y (TTM)-4.09%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%8.2%
Revenue 1Y (TTM)2.07%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%0.29%
3.2 Future
Based on estimates for the next years, TEVA will show a small growth in Earnings Per Share. The EPS will grow by 6.98% on average per year.
The Revenue is expected to grow by 1.96% on average over the next years.
EPS Next Y5.48%
EPS Next 2Y4.97%
EPS Next 3Y6.98%
EPS Next 5YN/A
Revenue Next Year3.05%
Revenue Next 2Y1.85%
Revenue Next 3Y1.96%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 9.43, the valuation of TEVA can be described as very reasonable.
Based on the Price/Earnings ratio, TEVA is valued cheaply inside the industry as 91.67% of the companies are valued more expensively.
TEVA is valuated cheaply when we compare the Price/Earnings ratio to 26.13, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 8.86, the valuation of TEVA can be described as reasonable.
TEVA's Price/Forward Earnings ratio is rather cheap when compared to the industry. TEVA is cheaper than 91.15% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.35, TEVA is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.43 | ||
| Fwd PE | 8.86 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TEVA indicates a rather cheap valuation: TEVA is cheaper than 91.15% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of TEVA indicates a rather cheap valuation: TEVA is cheaper than 81.77% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.71 | ||
| EV/EBITDA | 8.06 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
TEVA has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.72
PEG (5Y)N/A
EPS Next 2Y4.97%
EPS Next 3Y6.98%
5. Dividend
5.1 Amount
TEVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
24.6
+4.14 (+20.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners12.48%
Inst Owner Change0.27%
Ins Owners0.43%
Ins Owner Change-3.97%
Market Cap28.22B
Revenue(TTM)16.63B
Net Income(TTM)-158000000
Analysts42.22
Price Target0.06 (-99.76%)
Short Float %4.21%
Short Ratio4.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.24%
Min EPS beat(2)4.65%
Max EPS beat(2)5.84%
EPS beat(4)4
Avg EPS beat(4)3.88%
Min EPS beat(4)2.01%
Max EPS beat(4)5.84%
EPS beat(8)6
Avg EPS beat(8)4.79%
EPS beat(12)7
Avg EPS beat(12)-0.36%
EPS beat(16)9
Avg EPS beat(16)-0.6%
Revenue beat(2)0
Avg Revenue beat(2)-4.72%
Min Revenue beat(2)-4.77%
Max Revenue beat(2)-4.68%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-4.77%
Max Revenue beat(4)2.63%
Revenue beat(8)5
Avg Revenue beat(8)0.64%
Revenue beat(12)6
Avg Revenue beat(12)-0.39%
Revenue beat(16)6
Avg Revenue beat(16)-1.7%
PT rev (1m)2.21%
PT rev (3m)3.93%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.68%
EPS NY rev (1m)0%
EPS NY rev (3m)2.84%
Revenue NQ rev (1m)-0.74%
Revenue NQ rev (3m)-3.65%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.25%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.43 | ||
| Fwd PE | 8.86 | ||
| P/S | 1.7 | ||
| P/FCF | 31.71 | ||
| P/OCF | 20.3 | ||
| P/B | 4.13 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.06 |
EPS(TTM)2.61
EY10.61%
EPS(NY)2.78
Fwd EY11.29%
FCF(TTM)0.78
FCFY3.15%
OCF(TTM)1.21
OCFY4.93%
SpS14.5
BVpS5.95
TBVpS-11.56
PEG (NY)1.72
PEG (5Y)N/A
Graham Number18.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.39% | ||
| ROE | -2.31% | ||
| ROCE | 13.29% | ||
| ROIC | 10.49% | ||
| ROICexc | 11.36% | ||
| ROICexgc | 49.13% | ||
| OM | 22.59% | ||
| PM (TTM) | N/A | ||
| GM | 50.88% | ||
| FCFM | 5.35% |
ROA(3y)-3.67%
ROA(5y)-3.6%
ROE(3y)-23.1%
ROE(5y)-21.01%
ROIC(3y)9.12%
ROIC(5y)8.26%
ROICexc(3y)10.21%
ROICexc(5y)9.09%
ROICexgc(3y)56.98%
ROICexgc(5y)49.9%
ROCE(3y)11.55%
ROCE(5y)10.49%
ROICexgc growth 3Y25.78%
ROICexgc growth 5Y17.24%
ROICexc growth 3Y15.91%
ROICexc growth 5Y18.91%
OM growth 3Y0.25%
OM growth 5Y5.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.4%
GM growth 5Y2.35%
F-Score6
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.46 | ||
| Debt/FCF | 19.36 | ||
| Debt/EBITDA | 3.51 | ||
| Cap/Depr | 48.92% | ||
| Cap/Sales | 3.01% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 29.09% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.77 | ||
| Altman-Z | 0.66 |
F-Score6
WACC7.63%
ROIC/WACC1.37
Cap/Depr(3y)44.85%
Cap/Depr(5y)42.78%
Cap/Sales(3y)3.33%
Cap/Sales(5y)3.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.09%
EPS 3Y-1.18%
EPS 5YN/A
EPS Q2Q%8.2%
EPS Next Y5.48%
EPS Next 2Y4.97%
EPS Next 3Y6.98%
EPS Next 5YN/A
Revenue 1Y (TTM)2.07%
Revenue growth 3Y1.38%
Revenue growth 5Y-0.41%
Sales Q2Q%0.29%
Revenue Next Year3.05%
Revenue Next 2Y1.85%
Revenue Next 3Y1.96%
Revenue Next 5YN/A
EBIT growth 1Y1.19%
EBIT growth 3Y1.63%
EBIT growth 5Y5.48%
EBIT Next Year17.17%
EBIT Next 3Y7.55%
EBIT Next 5YN/A
FCF growth 1Y-24.19%
FCF growth 3Y46.96%
FCF growth 5Y27.42%
OCF growth 1Y-18.04%
OCF growth 3Y16.04%
OCF growth 5Y10.76%
TEVA PHARMACEUTICAL-SP ADR / TEVA FAQ
What is the fundamental rating for TEVA stock?
ChartMill assigns a fundamental rating of 4 / 10 to TEVA.
What is the valuation status for TEVA stock?
ChartMill assigns a valuation rating of 8 / 10 to TEVA PHARMACEUTICAL-SP ADR (TEVA). This can be considered as Undervalued.
Can you provide the profitability details for TEVA PHARMACEUTICAL-SP ADR?
TEVA PHARMACEUTICAL-SP ADR (TEVA) has a profitability rating of 6 / 10.
What is the valuation of TEVA PHARMACEUTICAL-SP ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for TEVA PHARMACEUTICAL-SP ADR (TEVA) is 9.43 and the Price/Book (PB) ratio is 4.13.
What is the financial health of TEVA PHARMACEUTICAL-SP ADR (TEVA) stock?
The financial health rating of TEVA PHARMACEUTICAL-SP ADR (TEVA) is 2 / 10.